// App-Quantinova.ai

: The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients

Researchers

Presenter

  • Clare Crean

Principal Investigators

  • Kienan I Savage

  • Ken I Mills

Medical Centers

  • Queen's University Belfast, Belfast, United Kingdom

  • Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom

  • Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Esophageal Cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • RAD51 Recombinase

Drug/Treatment

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved